Clinical Trials Directory

Trials / Completed

CompletedNCT05446532

Coexistence HBsAg/HBcAC, Clinical Characterístics & Outcomes

Characteristics of Hepatitis B HBsAg & HBsAc Carriers Simultaneously

Status
Completed
Phase
Study type
Observational
Enrollment
120 (actual)
Sponsor
Corporacion Parc Tauli · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

HBV infection is a dynamic process with complex interactions between virus replication and the host's immune response. The appearance of anti-HBs after HBV infection generally indicates recovery and immunity to HBV1 infection. However, there are several published studies that describe the coexistence of the marker of chronic infection (HBsAg +) and the marker of functional cure (HBsAc +). There are contradictory studies on whether the coexistence of HBsAg/HBsAc implies a different clinical course.

Conditions

Timeline

Start date
2022-06-15
Primary completion
2022-10-31
Completion
2022-12-31
First posted
2022-07-06
Last updated
2025-05-31

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT05446532. Inclusion in this directory is not an endorsement.

Coexistence HBsAg/HBcAC, Clinical Characterístics & Outcomes (NCT05446532) · Clinical Trials Directory